Dimitrov Anthony
Profectus BioSciences Inc, Techcenter at UMBC, Room 4011, 1450 South Rolling Road, Baltimore, MD 21227, USA.
Curr Opin Investig Drugs. 2007 Aug;8(8):653-61.
Tanox Inc (under license from Biogen Idec, formerly Biogen Inc) is developing ibalizumab, an intravenous, humanized, monoclonal antibody specific for CD4, for the potential treatment of HIV infection. In August 2006, the FDA advised Tanox to conduct additional dose-finding studies, from which data could potentially be used in a BLA filing. Ibalizumab had reached phase II clinical trials; however, there are currently no ongoing clinical trials.
Tanox公司（获得百健艾迪公司，前身为百健公司的许可）正在研发ibalizumab，这是一种针对CD4的静脉注射人源化单克隆抗体，用于潜在治疗HIV感染。2006年8月，美国食品药品监督管理局建议Tanox公司进行额外的剂量探索研究，其数据可能会用于生物制品许可申请。ibalizumab已进入II期临床试验；然而，目前没有正在进行的临床试验。
